We will not end childhood cancer alone—and we don’t intend to. We’re aligned with leading research institutions, the medical community, federal partners, philanthropists, patient families, and biopharmaceutical and technology firms that share our mission and understand our urgency. In this way, we aren’t just participating in progress; we’re driving it. This is how childhood cancer will end, once and for all: by working together. And we’re doing just that, focused on our roles as catalyst, advocate, and funder.
CATALYST
Bridge To A Cure Foundation has worked with federal agencies and policymakers to unlock the full potential of public sector leadership in childhood cancer research. Bridge To A Cure’s Bob Martin met with National Cancer Institute (NCI) director, Dr. Ned Sharpless, in October of 2017, helping to spark the Childhood Cancer Data Initiative (CCDI). We continue to drive a national strategy built on urgency, innovation, and equity, alongside the NCI, National Institutes of Health (NIH), Food and Drug Administration (FDA), and Congressional champions.
ADVOCATE
At Bridge To A Cure, we know science alone isn’t enough—policy must keep pace to prevent delays in lifesaving research. That’s why advocacy is central to our strategy. Working with partners like Smashing Walnuts and other invested childhood cancer foundations, we unite efforts to drive the national agenda and make childhood cancer a top government priority.
Bridge To A Cure advocacy has secured key legislative wins—including renewals of the Gabriella Miller Kids First Act and the STAR Act—while driving policies that boost funding, expand data access, and streamline FDA processes. We also helped advance the RACE for Children Act, which requires pediatric evaluation of cancer drugs, accelerating access to promising therapies.
FUNDER
Bridge To A Cure is deeply invested in advancing data-driven science to accelerate pediatric brain tumor research. Through active leadership on the Executive Council of the Children’s Brain Tumor Network, Bridge To A Cure has been instrumental in expanding this global coalition from 11 to 34 member institutions, partnering with 30 like-minded foundations to drive stable funding that supports this rapid growth. Bridge To A Cure also funded the Pediatric Cancer Data Commons to develop a universal pediatric brain tumor data lexicon, ensuring that research data is harmonized and accessible. Most recently, we’ve provided seed funding to build patient record pipelines that feed into RADIANT, an innovative AI-driven data ecosystem designed to transform childhood brain tumor studies and personalize care.
Catalyst. Advocate. Funder.
Bridge To A Cure drives progress as a catalyst, advocate, and funder to incite national initiatives, shape policy, and power data-driven research to end childhood cancer. Join us in accelerating this transformation with urgency and purpose.
